Back to Agenda
What the Day after Tomorrow Will Look Like When Patient Engagement in Medicines R&D Is Systematic, Meaningful and Sustainable
Session Chair(s)
Mathieu Boudes, PhD
Patient Engagement Director
Montsouris Consilium, France
This session will explore and anticipate what the systematic and meaningful patient engagement in medicines R&D will change in the development of new therapies for each stakeholders. Indeed, patient engagement, even though at the top of the agenda, is not yet fully implemented. The discussions will look at the day after tomorrow, when patient engagement will not be an advocacy topic anymore and has become the norm. The topics covered will (not exhaustively) be the putative nature changes of the medical expertise, its specificity of data gathering and by whom, the auditability and the subsequent trust in the data captured by patients themselves or patient organisations, the possible ‘Institutionalisation’ and independence of the patient organisations, the challenges due to the scale up of the current capacities in all stakeholders, new routes of patient organisations funding, the differential roles of online communities, patient experts and patient organisations, and many more (that needs to be discussed with each of the speakers).
Speaker(s)
Panelist
Violeta Stoyanova-Beninska, MD, PhD, MPH
Medicines Evaluation Board, Netherlands
Chair COMP EMA, Chair Scientific and Regulatory Advice MEB
Panelist
Yann Le Cam, MBA
Eurordis-Rare Diseases Europe, France
Chief Executive Officer
Panelist
Camilla Lauritzen
LEO Pharma , Denmark
Chief Patient Officer and Head of Patient Engagement
Have an account?